-
Mashup Score: 0
Lymphomas are heterogeneous tumors with striking genetic diversity and variable outcomes even within pathologic diagnoses. Treatment response assessment relies on radiologic and nuclear scans, which cannot detect disease at the molecular level. Molecular tumor analyses require invasive tissue biopsies that cannot accurately capture spatial tumor heterogeneity within each patient. Circulating…
Source: Blood Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0
Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma targeting B-cell maturation antigen ( TNFRSF17 ; BCMA) induces high overall response rates; however, relapse occurs commonly. A reservoir of multiple myeloma cells lacking sufficient BCMA surface expression (antigen escape) may be implicated in relapse. We demonstrate that simultaneous targeting of an additional antigen—here, G…
Source: Blood Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
3/ Study #2: Bicistronic >> tandem for BCMA & GPRC5D https://t.co/qRjypeuMjT CC: @ninashah33 @SandyWong02111 @NoopurRajeMD @szusmani @DrKrinaPatel @SurbhiSidanaMD @rajshekharucms @End_myeloma @ManniMD1 @bdermanmd @YLeyfman @DavidJChungMD @DMadduri
-
-
Mashup Score: 2Rare Sequences Make Sense of CAR T-cell Therapy Outcomes - 2 year(s) ago
Summary: In this issue, Pulsipher and colleagues used next-generation sequencing to detect leukemia-specific sequences following tisagenlecleucel therapy of acute lymphoblastic leukemia. A challenge for the field currently is to identify which patients will have therapy failure and to do so early enough to allow planning for further treatment, for example, stem cell transplantation. Detection of…
Source: Blood Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @BCD_AACR: #OnlineFirst: In the Spotlight, Rare sequences make sense of CAR T outcomes. https://t.co/6syRA9Pj7N @sghorashian @Dr_JB @Gre…
-
-
Mashup Score: 0CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity - 2 year(s) ago
To obtain a deeper understanding of poor responses to COVID-19 vaccination in lymphoma patients, we assessed blocking antibodies, total anti-spike IgG, and spike-specific memory B cells in the peripheral blood of 126 patients with lymphoma and 20 age-matched healthy controls 1 and 4 months after COVID-19 vaccination. Fifty-five percent of patients developed blocking antibodies post-vaccination,…
Source: Blood Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity [Jan 6, 2022] @tanaya_shree et al. @BCD_AACR https://t.co/DO5NYrWqL0 #COVID19Vaccine #COVID19nCancer #IDonc #lymsm #COVID19 HT @tobyeyre82 https://t.co/dQw0ZLdq6W
-
-
Mashup Score: 7
Lymphomas are heterogeneous tumors with striking genetic diversity and variable outcomes even within pathologic diagnoses. Treatment response assessment relies on radiologic and nuclear scans, which cannot detect disease at the molecular level. Molecular tumor analyses require invasive tissue biopsies that cannot accurately capture spatial tumor heterogeneity within each patient. Circulating…
Source: Blood Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @mozasp: Check out the latest review on ctDNA in lymphoma! https://t.co/8YrRmoesiX by @RoschewskiMD, Rossi, Kurtz, @AshAlizadeh, Wilso…
-
-
Mashup Score: 1CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity - 2 year(s) ago
To obtain a deeper understanding of poor responses to COVID-19 vaccination in lymphoma patients, we assessed blocking antibodies, total anti-spike IgG, and spike-specific memory B cells in the peripheral blood of 126 patients with lymphoma and 20 age-matched healthy controls 1 and 4 months after COVID-19 vaccination. Fifty-five percent of patients developed blocking antibodies post-vaccination,…
Source: Blood Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity https://t.co/0MSNlwjFAt
-
-
Mashup Score: 0
We assessed minimal residual disease (MRD) detection and B-cell aplasia after tisagenlecleucel therapy for acute lymphoblastic leukemia (ALL) to define biomarkers predictive of relapse ( N = 143). Next-generation sequencing (NGS) MRD detection >0 in bone marrow (BM) was highly associated with relapse. B-cell recovery [signifying loss of functional chimeric antigen receptor (CAR) T cells] within…
Source: Blood Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#NGS of #MRD Minimal Residual Disease for Predicting Relapse after Tisa-cel in Children and Young Adults with ALL https://t.co/cmksSanT89 #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @ASTCT @GruppSteve Great work!
-
-
Mashup Score: 0Rare Sequences Make Sense of CAR T-cell Therapy Outcomes - 2 year(s) ago
Summary: In this issue, Pulsipher and colleagues used next-generation sequencing to detect leukemia-specific sequences following tisagenlecleucel therapy of acute lymphoblastic leukemia. A challenge for the field currently is to identify which patients will have therapy failure and to do so early enough to allow planning for further treatment, for example, stem cell transplantation. Detection of…
Source: Blood Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Rare Sequences Make Sense of #CAR T-cell Therapy Outcomes https://t.co/5lONZpTuL2 #CART #bmtsm #CARTcell #immunotherapy #tcellrx #ICAN #CRS #CARTcells #CellTherapy #Gene #Genetherapy @sghorashian excellent work! https://t.co/EHrV4N6hlI
-
-
Mashup Score: 1Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with CAR T-cell Therapy - 2 year(s) ago
Summary: Here we review the pathophysiology and management of cytokine release syndrome (CRS) secondary to immunotherapy, and potential options for CRS refractory to IL6 inhibition and glucocorticoids, for which there are no proven treatments. To illustrate, we describe a patient with B-cell acute lymphoblastic leukemia who developed refractory grade 4 CRS following CD19-directed chimeric antigen…
Source: Blood Cancer DiscoveryCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Potential Role of IFNγ Inhibition in Refractory Cytokine Release Syndrome Associated with #CAR T-cell Therapy #CellTherapy https://t.co/mIMVKvzQm6
-
-
Mashup Score: 2CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity - 2 year(s) ago
To obtain a deeper understanding of poor responses to COVID-19 vaccination in lymphoma patients, we assessed blocking antibodies, total anti-spike IgG, and spike-specific memory B cells in the peripheral blood of 126 patients with lymphoma and 20 age-matched healthy controls 1 and 4 months after COVID-19 vaccination. Fifty-five percent of patients developed blocking antibodies post-vaccination,…
Source: Blood Cancer DiscoveryCategories: Hem/Oncs, Latest HeadlinesTweet-
We are recommending vaccinating/boosting before treatment in all who can wait a little before starting anti-CD20-based treatment and haven't yet been vaccinated/boosted. Full manuscript @BCD_AACR: https://t.co/zqi6nh6lfr /end
-
#Hematology Circulating Tumor DNA in Lymphoma: Principles and Future Directions #lymsm #ctDNA #LiquidBiopsy https://t.co/SszGrcwGor